Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 6/20 | 0.61 |
| ▸ | KDR | P35968 | 10/20 | 0.46 |
| ▸ | PLK1 | P53350 | 7/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970864 | 0.86 | FGFR1 (0.49) | FGFR4KDRPLK1FGFR1FGFR2 | |
| SCHEMBL24490202 | 0.85 | FGFR4 (0.56) | FGFR4FGFR1FGFR2FGFR3BRD4 | |
| SCHEMBL5768493 | 0.82 | FGFR4 (0.57) | FGFR4KDRPLK1PDGFRBFGFR1 | |
| SCHEMBL3972648 | 0.82 | FGFR4 (0.57) | FGFR4KDRFGFR1FGFR2FGFR3 | |
| SCHEMBL3967389 | 0.82 | LCK (0.54) | FGFR4KDRPDGFRBFGFR1FGFR2 | |
| SCHEMBL3971372 | 0.81 | FGFR4 (0.51) | FGFR4KDRFGFR1FGFR2FGFR3 | |
| SCHEMBL3968277 | 0.79 | FGFR4 (0.65) | FGFR4KDRPDGFRBFGFR1FGFR2 | |
| SCHEMBL16134003 | 0.76 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL3971040 | 0.76 | FGFR4 (0.64) | FGFR4KDRFGFR1FGFR2FGFR3 | |
| SCHEMBL3971418 | 0.75 | FGFR4 (0.52) | FGFR4KDRFGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | FGFR4 95/4885KDR 66/4885PLK1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.